210 related articles for article (PubMed ID: 36228414)
1. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1.
Zhou Q; Wu W; Jia K; Qi G; Sun XS; Li P
Eur J Med Chem; 2022 Dec; 244():114830. PubMed ID: 36228414
[TBL] [Abstract][Full Text] [Related]
2. Structure-based Discovery of Cell-Potent Peptidomimetic Inhibitors for Protein N-Terminal Methyltransferase 1.
Chen D; Dong G; Deng Y; Noinaj N; Huang R
ACS Med Chem Lett; 2021 Mar; 12(3):485-493. PubMed ID: 33738076
[TBL] [Abstract][Full Text] [Related]
3. Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal Methyltransferase 1.
Dong G; Iyamu ID; Vilseck JZ; Chen D; Huang R
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209173
[TBL] [Abstract][Full Text] [Related]
4. Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.
Shen Y; Gao G; Yu X; Kim H; Wang L; Xie L; Schwarz M; Chen X; Guccione E; Liu J; Bedford MT; Jin J
J Med Chem; 2020 Sep; 63(17):9977-9989. PubMed ID: 32787082
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer.
Bi K; Cheng J; He S; Fang Y; Huang M; Sheng C; Dong G
J Med Chem; 2023 Jan; 66(1):1048-1062. PubMed ID: 36563407
[TBL] [Abstract][Full Text] [Related]
7. Selective Peptidomimetic Inhibitors of NTMT1/2: Rational Design, Synthesis, Characterization, and Crystallographic Studies.
Mackie BD; Chen D; Dong G; Dong C; Parker H; Schaner Tooley CE; Noinaj N; Min J; Huang R
J Med Chem; 2020 Sep; 63(17):9512-9522. PubMed ID: 32689795
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.
Wang XR; Wang S; Mu HX; Xu KY; Wang XT; Shi JT; Cui QH; Zhang LW; Chen SW
Eur J Med Chem; 2022 Dec; 244():114821. PubMed ID: 36242985
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
Kato JY; Korenaga S; Iwakura M
Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177
[TBL] [Abstract][Full Text] [Related]
11. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2.
Liu X; Kalogeropulou AF; Domingos S; Makukhin N; Nirujogi RS; Singh F; Shpiro N; Saalfrank A; Sammler E; Ganley IG; Moreira R; Alessi DR; Ciulli A
J Am Chem Soc; 2022 Sep; 144(37):16930-16952. PubMed ID: 36007011
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and kinetic analysis of potent protein N-terminal methyltransferase 1 inhibitors.
Zhang G; Richardson SL; Mao Y; Huang R
Org Biomol Chem; 2015 Apr; 13(14):4149-54. PubMed ID: 25712161
[TBL] [Abstract][Full Text] [Related]
13. Venglustat Inhibits Protein N-Terminal Methyltransferase 1 in a Substrate-Competitive Manner.
Dong G; Deng Y; Yasgar A; Yadav R; Talley D; Zakharov AV; Jain S; Rai G; Noinaj N; Simeonov A; Huang R
J Med Chem; 2022 Sep; 65(18):12334-12345. PubMed ID: 36074125
[TBL] [Abstract][Full Text] [Related]
14. Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders.
Xie H; Bacabac MS; Ma M; Kim EJ; Wang Y; Wu W; Li L; Xu W; Tang W
J Med Chem; 2023 Sep; 66(18):13028-13042. PubMed ID: 37703322
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.
Yu X; Xu J; Xie L; Wang L; Shen Y; Cahuzac KM; Chen X; Liu J; Parsons RE; Jin J
J Med Chem; 2021 Dec; 64(24):18054-18081. PubMed ID: 34855399
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.
Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
[TBL] [Abstract][Full Text] [Related]
17. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
Sun Y; Zhang Y; Chen X; Yu A; Du W; Huang Y; Wu F; Yu L; Li J; Wen C; Yang H; Shi Q; Geng M; Huang X; Xu S
Eur J Med Chem; 2022 Sep; 239():114528. PubMed ID: 35717870
[TBL] [Abstract][Full Text] [Related]
19. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
20. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
